← Back to Search

Brain Stimulation

Brain Stimulation for Depression

N/A
Recruiting
Research Sponsored by University of California, Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Accompanied by at least two evidence-based augmentation therapies (Benzodiazepines do not count)
Must have confirmed diagnosis of moderate Major Depressive Disorder (single or recurrent episode), minimum score of 17 on the 17-item Hamilton Rating Scale for Depression (HAM-D17). No minimal MDD duration necessary for study participation
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, average of 6 weeks
Awards & highlights

Study Summary

This trial will study the effects of brain stimulation on pain symptoms in people with Major Depressive Disorder. 69 people will receive 30 treatments of transcranial magnetic stimulation and will be compensated $150 for their time.

Who is the study for?
This trial is for adults aged 18-75 with chronic pain and moderate Major Depressive Disorder who haven't improved after at least two different antidepressant medications and psychotherapy. Participants must speak English, be right-handed, have a specific depression score, and not respond to other treatments including psychotherapy.Check my eligibility
What is being tested?
The study tests the effects of brain stimulation (rTMS/iTBS) on pain in those with depression. All participants receive active treatment over approximately 30 sessions. They'll complete surveys, undergo blood draws, MRIs, EEGs, and dedicate about 40 hours across up to 33 visits.See study design
What are the potential side effects?
Potential side effects may include discomfort at the stimulation site on the scalp, headache or dizziness post-treatment. There's also a small risk of seizure associated with magnetic stimulation but this is rare.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am receiving two or more approved additional treatments (not including Benzodiazepines).
Select...
I have been diagnosed with moderate depression and scored at least 17 on the HAM-D17.
Select...
I have been diagnosed with FM or ME/CFS and experience moderate pain.
Select...
My condition did not improve after trying two different types of treatment.
Select...
I have tried at least 2 antidepressants without success.
Select...
I am between 18 and 75 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, average of 6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, average of 6 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent change in depression scores
Percent change in pain score
Secondary outcome measures
Levels of inflammatory markers and transcription factors

Trial Design

2Treatment groups
Experimental Treatment
Group I: Active rTMS/Active iTBS DFPLC/Sham Pain M1Experimental Treatment1 Intervention
Group II: Active rTMS/Active iTBSExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

University of California, Los AngelesLead Sponsor
1,530 Previous Clinical Trials
10,264,654 Total Patients Enrolled
101 Trials studying Depression
48,389 Patients Enrolled for Depression

Media Library

Active rTMS/Active iTBS (Brain Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT04556890 — N/A
Depression Research Study Groups: Active rTMS/Active iTBS DFPLC/Sham Pain M1, Active rTMS/Active iTBS
Depression Clinical Trial 2023: Active rTMS/Active iTBS Highlights & Side Effects. Trial Name: NCT04556890 — N/A
Active rTMS/Active iTBS (Brain Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04556890 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Do I meet the qualifications to join this experiment?

"This clinical trial is recruiting 69 individuals aged 18 to 75 that experience chronic pain. Applicants must possess a verified Major Depressive Disorder (single or recurrent episode) with a minimum score of 17 on the Hamilton Rating Scale for Depression, confirmation of Fibromyalgia/Myalgic Encephalomyelitis and Chronic fatigue syndrome along with moderate pain complaints as demonstrated by a 15+ McGill Pain Questionnaire rating. Furthermore, all participants are required to be right-handed and have failed response from two separate medication classes in addition to undergoing an adequate frequency and duration of psychotherapy known for treating MDD. Finally, applicants need evidence-based"

Answered by AI

Does this research encompass individuals of advanced age?

"According to the study's selection criteria, only adults between 18 and 75 are eligible for enrollment."

Answered by AI

Are there still vacancies for participants in this research project?

"According to the information provided on clinicaltrials.gov, this study is not currently accepting participants. Initially posted in December 30th 2022 and last edited October 11st 2022, this trial does not have any openings at present time; however there are 1,684 different clinical trials which are presently looking for patients."

Answered by AI

Who else is applying?

What site did they apply to?
UCLA Semel Institute
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Pain and Major Depressive Disorder
Juliana Corlier, PhD 2023. "Pain and Major Depressive Disorder". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04556890.
All > Depression Los Angeles > Chronic Pain
~36 spots leftby Dec 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top